At Phebra, we create critical medicines that save and improve lives.
Phebra specialises in the development, manufacture, marketing and distribution of highly specialised and innovative medicines for the hospital market.
At Phebra, our inspiration and commitment comes from providing medicines for serious and life-threatening conditions. We pride ourselves in developing and providing high quality pharmaceuticals to meet the requirements of the hospital specialty pharmaceutical market.
Phebra markets a range of products in the following therapeutic areas:
- cardiovascular and respiratory disease
- central nervous system
- diagnostic dyes and agents
- infusion solutions, intravenous additives and electrolyte replacement solutions
- oncology and pain
- specialty pharmaceuticals
Phebra is a privately owned pharmaceutical company, founded in 1993 as distributor of speciality pharmaceutical products. It was known then as Pharmalab.
In 1998, Pharmalab purchased Ophthalmic Laboratories Pty Ltd, a small volume injectables and ophthalmic facility in Brookvale, New South Wales, as a manufacturing base. Pharmalab developed a formulation and manufacturing facility and manufactured many critical pharmaceuticals being sought by hospitals. These were often products that were not being made available or were being deleted from other company’s product ranges due to their low sale volumes.
In 2000, Pharmalab acquired the Tuta Australian operations of Otsuka Pharmaceuticals of Japan. Tuta Australia was a medical devices and liquids manufacturing operation at Lane Cove, Sydney. This acquisition provided the site for a new sterile injectables manufacturing plant that was constructed and commissioned in 2002.
In 2007, Pharmalab changed its name to Phebra to reflect the growth and globalisation of its business. Phebra is taken from the names of two important gods: Februus was an ancient Roman mythological deity who commanded the role of purification; and the goddess Febris was a protector against fevers and malaria. Our logo for Phebra is phi from the Greek alphabet and represents the golden ratio, a simple but important equation which has fascinated philosophers, builders and scientists since Pythagoras’ day. Phebra and the symbol phi stand for quality, protection and purity, values which are very important to the team at Phebra.
Phebra is focussed on marketing specialty pharmaceuticals to the hospital market in Australia and via distributers in New Zealand, Asia, Canada and Europe.
Phebra is actively licensing specialty pharmaceutical products to market and distribute in the Asia Pacific region. We have successful partnerships with:
- Regional specialty pharmaceutical companies with no representation in the Asia Pacific region who are looking for a commercialisation partner;
- Multinational pharmaceutical companies that wish to divest proprietary products;
- Biotech companies with products in late-stage clinical development.
Our business focus is hospital specialty pharmaceuticals particularly in the areas of:
- Niche Specialty Pharmaceuticals
Phebra is interested in working with companies to commercialise its product range and is interested in discussing out-licensing.
If you have an in-licensing or out-licensing query, please contact us at:
Phebra offers a large range of sterile injectable pharmaceuticals manufactured in its facility in Sydney, Australia. Phebra also manufactures a number of active pharmaceutical ingredients at this site. Our facilities are licensed and approved by the Australian Therapeutic Goods Administration. Phebra also has a license from the Australian Pesticides and Veterinary Medicines Authority for the production of veterinary products.
Phebra maintains a research and development facility in Sydney that allows us to develop products upon request. Our product development and regulatory teams can assist with concepts of design, packaging and product development, as well as filling and supply for clinical trials.
Phebra’s New Manufacturing Plant
Our new $25 million sterile manufacturing facility at Lane Cove West was officially opened on the 8th of March 2013.
The new facility will further enhance our research and development programmes and our capacity to manufacture critical medicines for local and export markets.
We welcome discussion of any innovative ideas or products. For more information on how we can help you, please contact us for a confidential discussion at: email@example.com